| Matt Scott wins big for Dr. Mel Fund |
|
|
| Written by Jeff Bailey | |
| Saturday, 14 April 2007 | |
|
Once again the poker playing skills of WTNH-TV meterologist Matt Scott have helped to grow the Dr. Mel Goldstein Multiple Myeloma Fund.
Matt finished in second place March 28, 2007, at the annual Foxwoods Poker Classic Charity Media Showdown. He collected a check for $7,000.
Over the years Matt has donated thousands of dollars in winnings to the fund, to which we say thank you, thank you, once again. And just because we know you'd be curious, this year's winner was reporter Jim Altman from WTIC-TV in Hartford. He collected $15,000 for his charity, The Fox 61 Family Fund. |
| < Prev | Next > |
|---|
Multiple Myeloma News Update
-
Research forum Sept. 16 to focus on multiple myeloma
UConn Advance, CT - 2 hours ago
... research forum focusing on issues related to contemporary clinical and investigative approaches to multiple myeloma will take place on Tuesday, Sept. ... -

Network MédicaBiogen Idec and Elan Corp Announce Start of Trials with Tysabri as ...
Network Médica, Argentina - 2 hours ago
The treatments for multiple myeloma are led by biotech Celgene, with several drugs on the market: Revlimid, with sales for $ 613 million dollars in the ... -

Network MédicaBiogen to test Tysabri as a cancer treatment
Bizjournals.com, NC - 4 hours ago
Eligible candidates must have multiple myeloma and have failed with previous treatments. Biogen Idec makes Tysabri at a manufacturing plant in Research ...
Biogen’s battered MS drug in cancer treatment trials Mass High Tech
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in ... elEconomista.es
Tysabri clinical study underway Hays Pharma
Pharma Times (subscription)all 37 news articles -
Bortezomib plus melphalan-prednisone improved response rate in ...
HemOncToday, NJ - 9 hours ago
Melphalan and prednisone plus bortezomib may improve time to progression in patients with newly diagnosed multiple myeloma. According to researchers from ... -
Elan, Biogen Idec commence first clinical trial of Tysabri in ...
RTT News, NY - 15 hours ago
Patients with eighteen years and above suffering from relapsed or refractory multiple myeloma and those who failed or cannot tolerate therapy with ... -
Elan, Biogen launch Tysabri trial in oncology
Reuters - 16 hours ago
The first dose was administered on Thursday, they said. Multiple myeloma is a cancer of the plasma cell. (Reporting by Jonathan Saul; Editing by Quentin Bryar) -
Human Genome Sciences reports initial results from Phase II ...
Pharmaceutical Business Review - 21 hours ago
By Staff Writer The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for ... -
Human Genome Sciences Reports Initial Results Of Randomized Phase ...
Medical News Today (press release), UK - Sep 4, 2008
The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination ...













The event took place during the Foxwoods Poker Classic, an event on the World Poker Tour.